These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29956453)

  • 41. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues.
    Sankoh AJ; D'Agostino RB; Huque MF
    Stat Med; 2003 Oct; 22(20):3133-50. PubMed ID: 14518019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.
    Brosteanu O; Houben P; Ihrig K; Ohmann C; Paulus U; Pfistner B; Schwarz G; Strenge-Hesse A; Zettelmeyer U
    Clin Trials; 2009 Dec; 6(6):585-96. PubMed ID: 19897532
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Bayesian approach for event predictions in clinical trials with time-to-event outcomes.
    Aubel P; Antigny M; Fougeray R; Dubois F; Saint-Hilary G
    Stat Med; 2021 Dec; 40(28):6344-6359. PubMed ID: 34541701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sample size planning for phase II trials based on success probabilities for phase III.
    Götte H; Schüler A; Kirchner M; Kieser M
    Pharm Stat; 2015; 14(6):515-24. PubMed ID: 26412484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A proposed approach for quantitative benefit-risk assessment in diagnostic radiology guideline development: the American College of Radiology Appropriateness Criteria Example.
    Agapova M; Bresnahan BB; Higashi M; Kessler L; Garrison LP; Devine B
    J Eval Clin Pract; 2017 Feb; 23(1):128-138. PubMed ID: 27762080
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours.
    Shakespeare TP; Gebski VJ; Veness MJ; Simes J
    Lancet; 2001 Apr; 357(9265):1349-53. PubMed ID: 11343760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
    Naci H; Ioannidis JP
    Annu Rev Pharmacol Toxicol; 2015; 55():169-89. PubMed ID: 25149917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sample size and the probability of a successful trial.
    Chuang-Stein C
    Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The "Coming of Age" of Real-World Evidence in Drug Development and Regulation.
    Honig PK
    Clin Pharmacol Ther; 2022 Jan; 111(1):11-14. PubMed ID: 34914104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of composite endpoints in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2014 Nov; 33(27):4709-14. PubMed ID: 24833282
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysis.
    Li K; Yuan SS; Wang W; Wan SS; Ceesay P; Heyse JF; Mt-Isa S; Luo S
    Contemp Clin Trials; 2018 Apr; 67():100-108. PubMed ID: 29505866
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development.
    Gibbs JP; Menon R; Kasichayanula S
    Clin Pharmacol Ther; 2018 Feb; 103(2):196-198. PubMed ID: 29105747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recommendations for benefit-risk assessment methodologies and visual representations.
    Hughes D; Waddingham E; Mt-Isa S; Goginsky A; Chan E; Downey GF; Hallgreen CE; Hockley KS; Juhaeri J; Lieftucht A; Metcalf MA; Noel RA; Phillips LD; Ashby D; Micaleff A;
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):251-62. PubMed ID: 26800458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sequentially updating the likelihood of success of a Phase 3 pivotal time-to-event trial based on interim analyses or external information.
    Rufibach K; Jordan P; Abt M
    J Biopharm Stat; 2016; 26(2):191-201. PubMed ID: 25372950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials.
    Mallinckrodt CH; Raskin J; Wohlreich MM; Watkin JG; Detke MJ
    BMC Psychiatry; 2004 Sep; 4():26. PubMed ID: 15355546
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.